THE CURRENT APPLICATION OF THE MYRIAD AND MAYO/ALICE RULINGS ON PATENT ELIGIBILITY: INCONSISTENT RESULTS AND CONTRADISTINGUISHING BIOTECHNOLOGY PRODUCTS.

The article provides an overview of brief and informative scientific overview of DNA, RNA, and cDNA, and a history of gene patents in the U.S. It mentions about the development of a judicial exception to patent ineligibility using the framework provided by court cases Ass'n for Molecular Pathology v. Myriad Genetics, Inc., Mayo Collaborative Servs. v. Prometheus Laboratories, Inc., and Alice Corp. Pty. Ltd. v. CLS Bank Int'l.